[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 2 sources · 13 days · First seen · Last updated

Tezspire clinical trial results for EoE

Overview

Clinical trial results from the phase III CROSSING study indicate that tezepelumab (Tezspire), developed by AstraZeneca and Amgen, shows significant improvement for adolescents and adults with symptomatic, uncontrolled eosinophilic esophagitis (EoE).

Data presented at the United European Gastroenterology Week 2026 showed that patients receiving doses of 210 mg or 420 mg achieved histological remission rates of 64.8% and 68.9% respectively at week 24, compared to 3.5% in the placebo group. These efficacy levels were maintained through week 52. The treatment, administered subcutaneously every four weeks, also reduced the frequency and severity of dysphagia, or difficulty swallowing, according to the Dysphagia Symptom Questionnaire.

Entities

AstraZeneca · Amgen · TEZSPIRE · United European Gastroenterology · Tepezza

Timeline

  1. [HEALTH] 2 sources
    Amgen and AstraZeneca report positive clinical trial results for specialized therapies

    Amgen's Tepezza is now listed on Australia's PBS for thyroid eye disease, while Tezspire shows success in treating eosinophilic oesophagitis in phase 3 trials.

  2. [HEALTH] 4 sources
    Tezspire shows clinical improvement in eosinophilic esophagitis patients

    Phase III CROSSING trial results show tezepelumab significantly improves histological remission and reduces dysphagia symptoms in patients with eosinophilic esophagitis.

Sources

insightnews.com.au · pharmafile.com